EUVIMEDEUVIMED entdecken
Crossref

First time ACS in patients with on‐target lipid levels: Inflammation at admission and re‐event rate at follow‐up

Natàlia Muñoz-García iD, Alberto Cordero iD, Teresa Padro iD, Guiomar Mendieta, Gemma Vilahur iD, Emilio Flores iD, Lina Badimon iD

European Journal of Clinical Investigation · 2024

DOI: 10.1111/eci.14305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Natàlia Muñoz-García und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, Barcelona, Spain. Hauptthemen laut MEDLINE: Inflammation, Lipoprotein(a), Acute Coronary Syndrome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Generalitat de Catalunya, Agencia Estatal de Investigación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dyslipidaemia, inflammation and elevated Lp(a) levels are associated with the progression of atherosclerosis. This study investigates whether patients with a first‐time presentation of chest pain and on‐target LDL‐C levels and intermediate FRS/ESC‐Score risks, display a high inflammatory burden linked to myocardial injury and whether inflammation at admission affects the re‐event rate up to 6 years follow‐up.

Methods

Blind assessments of novel inflammatory markers such as Glycoprotein A and B via nuclear magnetic resonance (NMR), cytokines, hsCRP, Neutrophil‐to‐Lymphocyte ratio (NLR) and Lipoprotein(a) levels were examined. Out of 198 chest pain patients screened, 97 met the inclusion criteria at admission. Results cTnI(+) patients (>61 ng/L) with elevated Lipoprotein(a), showed significantly increased levels of Glycoprotein A and B, hsCRP, IL‐6, a high NLR and a reduced left ventricular ejection fraction (%) compared to cTnI(−) individuals. Those patients, with a higher inflammatory burden at hospital admission (hsCRP, IL‐6, Glycoprotein A and B, and Lipoprotein(a)) had a higher re‐event rate at follow‐up.

Conclusions

Inflammation and Lipoprotein(a) levels were particularly prominent in patients presenting with reduced left ventricular ejection fraction. Notably, Glycoproteins A/B emerge as novel markers of inflammation in these patients. Our study highlights the significantly higher impact of inflammatory burden in patients with chest pain and high level of myocardial damage than in those with lower myocardial affectation, even when they all had lipid levels well controlled. Inflammation at the time of admission influenced the re‐event rate over a follow‐up period of up to 6 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InflammationLipoprotein(a)Acute Coronary SyndromeHumansMaleFemaleMiddle AgedFollow-Up StudiesAgedBiomarkersCholesterol, LDLChest PainC-Reactive ProteinInterleukin-6RecurrenceStroke VolumeDyslipidemias

Stichwörter der Autor:innen

ACSLVEFMACEinflammationlipoprotein(a)troponins

Substanzen

Lipoprotein(a)BiomarkersCholesterol, LDLC-Reactive ProteinInterleukin-6

Autor:innen und Institutionen

  • Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, Barcelona, Spain.
  • Medical School, Universtitat de Barcelona, Barcelona, Spain.
  • Cardiology Department, Hospital IMED Elche, Elche, Spain.
  • Unidad de Investigación en Cardiología. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), València, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
  • Cardiology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain.

ORCID-Profile: Natàlia Muñoz-García, Alberto Cordero, Teresa Padro, Gemma Vilahur, Emilio Flores, Lina Badimon

Förderung

  • Instituto de Salud Carlos III
  • Generalitat de Catalunya
  • Agencia Estatal de Investigación
  • Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares
  • Sociedad Española de Cardiología
  • Sociedad Valenciana de Cardiología

Zitieren

APA

Muñoz-García, N., Cordero, A., Padro, T., Mendieta, G., Vilahur, G., Flores, E., & Badimon, L. (2024). First time ACS in patients with on‐target lipid levels: Inflammation at admission and re‐event rate at follow‐up. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14305

Vancouver

Muñoz-García N, Cordero A, Padro T, Mendieta G, Vilahur G, Flores E, et al. First time ACS in patients with on‐target lipid levels: Inflammation at admission and re‐event rate at follow‐up. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14305

BibTeX
@article{MuozGarca2024,
  author = {Muñoz-García, Natàlia and Cordero, Alberto and Padro, Teresa and Mendieta, Guiomar and Vilahur, Gemma and Flores, Emilio and Badimon, Lina},
  title = {First time ACS in patients with on‐target lipid levels: Inflammation at admission and re‐event rate at follow‐up},
  journal = {European Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1111/eci.14305}
}
Kostenlos starten →